Gliknik Inc., a Baltimore, MD-based biopharmaceuticals company creating new cancer and immune disorder therapies, has raised $3.5m in equity financing.
Existing investor Joel B. Braunstein, M.D., M.B.A., participated in this round.
The company intends to use the funds to initiate a clinical program in autoimmune diseases for its lead recombinant candidate from its stradomer™ platform. GL-2045, which is in preclinical development, has demonstrated efficacy in animal models of inflammation and autoimmunity and is expected to have clinical utility in different diseases.
Founded in 2007, Gliknik is led by President and CEO David S. Block.